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Multiple effects of HMG-CoA 
reductase inhibitors (statins) 
besides their lipid-lowering function
Bettina Haslinger-Löffler1
The paper by Sharyo et al. shows that statins reduce the severity in a 
model of renal–ischemia reperfusion injury and raises the therapeutic 
possibility of using statins as pharmacological intervention against acute 
kidney injury. This, together with previous studies, indicates that statins 
exert a wide spectrum of anti-inflammatory, immunomodulatory, and 
protective effects besides their lipid-lowering function.
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Inhibitors of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase (stat-
ins) have become the most widely used 
drugs for lowering serum cholesterol levels, 
applied to at least 15% of patients admitted 
to hospitals.1 They are mainly used for pre-
vention of cardiovascular events, and they 
have proved to be highly effective. How-
ever, clinical studies demonstrated that the 
statin-mediated lowering of cholesterol 
and triglycerides appeared to account for 
many but not all of the beneficial effects 
in cardiovascular diseases.2 Furthermore, 
statins improve the outcome of vascular 
diseases, some of which are not associated 
with elevated lipid levels—for example, 
stroke and transplantation-associated 
coronary vasculopathy.2,3 These observa-
tions led to the hypothesis that statins do 
not only improve the lipid profile but also 
have direct vascular and tissue-protective 
actions. In this regard, Sharyo et al.4 (this 
issue) demonstrated in a renal ischemia–
reperfusion injury mouse model that 
pravastatin ameliorated renal function 
and injury independent of plasma cho-
lesterol levels. They also report that prav-
astatin prevented the increase in plasma 
interleukin-6 levels induced by ischemic 
kidney injury.4 As interleukin-6 is an 
important regulator of acute inflammatory 
reactions, these findings are in line with 
many other published works demonstrat-
ing anti-inflammatory actions of statins.2 
Especially in vitro studies with different cell 
types support lipid-lowering–independent 
functions of statins: It has been shown 
that statins can interfere with leukocyte–
endothelial interactions and prevent the 
adhesion and migration of leukocytes to 
the inflammatory side. As Sharyo et al.4 
mention, simvastatin can bind directly to 
leukocyte function antigen-1 (LFA-1) and 
inhibit leukocyte adhesion.5 This function 
is completely independent of blocking the 
activity of HMG-CoA reductase and lipid 
lowering (Figure 1). Additionally, statins 
were found to diminish the expression of 
various cytokines, such as interleukin-6 or 
tumor necrosis factor-α, in macrophages. 
But also in non-professional phagocytes, 
for example, endothelial cells and smooth 
muscle cells, the expression of chemotac-
tic and proinflammatory mediators, such 
as monocyte chemoattractant protein-1 
and interleukin-8, could be reduced by the 
use of statins.2 Furthermore, statins have 
been shown to interfere with the genera-
tion of reactive oxygen species or to acti-
vate scavenging systems for free radicals, 
such as the thioredoxin system. Especially 
with regard to the vascular system, many 
additional proangiogenic and protective 
properties of statins have been reported, 
including many beneficial effects on re-
endothelialization following vessel injury 
and inhibition of platelet aggregation in 
diseased vessel walls.2,6 Because of the 
diverse anti-inflammatory and vasopro-
tective properties, it was suggested to use 
statins not only for the treatment of vas-
cular diseases but also in infected or septic 
patients. Recent work even demonstrated 
antimicrobial actions of statins.7
Inflammatory processes, especially the 
release of proinflammatory cytokines, 
essentially regulate tissue remodeling and 
wound healing. The formation and deposi-
tion of fibrin is part of the hemostatic proc-
ess in response to inflammation and tissue 
injury. However, when the fibrin is not 
removed because of an insufficient fibrino-
lytic activity, it becomes organized. This can 
result in fibrous tissue remodeling with loss 
of organ function. In different cell types, 
including endothelial cells, smooth mus-
cle cells, and proximal tubular cells, statins 
efficiently promote the fibrinolytic activity 
by diminishing the expression of plasmino-
gen activator inhibitor-1 and of the proco-
agulant tissue factor and by enhancing that 
of tissue-type plasminogen activator.2,8,9 In 
this way statins might help to remove fibrin 
deposits and recover organ function. Fur-
thermore, statins are supposed to interfere 
with matrix turnover. The breakdown of 
matrix is essentially mediated by a family 
554   Kidney International (2008) 74 
commentar y
of matrix-degrading enzymes, the matrix 
metalloproteinases (MMPs). Studies with 
different cell types, including endothelial 
cells and macrophages, demonstrate that 
statins lower the expression and function 
of a wide range of MMPs. However, the 
enzymatic activity of MMPs is dependent 
not only on the expression of the protease 
but also on its interaction with the endog-
enous tissue inhibitors of MMPs (TIMPs). 
As statins were found to decrease the 
expression of MMPs and to augment the 
expression of TIMPs, they probably limit 
extracellular matrix breakdown and func-
tion to preserve tissue.2
Downregulated inflammatory reactions 
and improved endothelial functions medi-
ated by statins are considered to account 
for the better outcome of vascular diseases. 
However, it has not been well investigated 
whether statins confer similar benefits to 
the kidney. The work of Sharyo et al.4 sug-
gests that statins might induce similar anti-
inflammatory and tissue-protective actions 
in the kidney. Acute kidney injury is most 
likely followed by multiple processes, 
including the generation of reactive oxy-
gen species, nitric oxide, and the decline of 
antioxidant protection, which can result in 
dysfunction, injury, and death of the cells 
of the kidney. Renal inflammation involv-
ing cytokine/adhesion molecule expression 
with recruitment, activation, and diapedesis 
of circulating leukocytes is also implicated. 
Thus, statins might improve acute kidney 
injury through direct effects on the renal 
vasculature, protection of tubular cells, and 
a systemic anti-inflammatory effect.10
The molecular mechanisms underly-
ing the proinflammatory and protective 
actions of statins are only partly known. 
Statins prevent the conversion of HMG-
CoA to mevalonic acid, and hence also the 
synthesis of bioactive sterol and nonsterol 
metabolic intermediates deriving from this 
pathway (Figure 1). Proximal inhibition of 
this pathway reduces the production of iso-
prenoids such as farnesyl pyrophosphate 
and geranylgeranyl pyrophosphate. Isopre-
noids are required for the post-translational 
‘prenylation’ and membrane localization 
of small guanosine triphosphate-binding 
proteins. ‘Prenylation’ means lipid modi-
fications with covalent binding of farnesyl 
or geranylgeranyl isoprenoids to conserved 
cysteine residues of proteins. These proteins 
include a wide range of signal transducers, 
including Ras and Ras-related guanosine 
triphosphate-binding (G) proteins such 
as Rho, which interfere with numerous 
inflammatory pathways. Statins inhibit the 
formation of farnesylated and geranylger-
anylated proteins by blocking the meval-
onate pathway.2 Many anti-inflammatory 
and vasoprotective actions of statins can be 
reversed by exogenous geranylgeranyl or 
farnesyl pyrophosphate, demonstrating the 
involvement of the mevalonate pathway in 
the statins’ mode of action. These functions 
include leukocyte adhesion, cell viability, 
cell proliferation, and the fibrinolytic activ-
ity.2,8 In line with these findings, Sharyo et 
al.4 report that a farnesyl transferase inhibi-
tor improved renal dysfunction to a degree 
comparable to that seen with the use of 
statins. Furthermore, different studies show 
that statins downregulate the activity of 
the transcription factors nuclear factor-κB 
and activator protein-1, which also play an 
important role in the regulation of many 
inflammatory pathways.2,9
Taken together with previous work, the 
work of Sharyo et al.4 demonstrates that 
statins improve renal dysfunction after 
acute kidney injury by a lipid-lowering–
independent effect. Most likely this action 
of statins is due to anti-inflammatory 
properties and dependent on the meval-
onate pathway. Further studies of the 
pleiotropic functions of statins may help 
to explain the involved mechanisms in 
more detail. A better understanding of the 
statins’ mode of action may help to develop 
novel therapeutic strategies for various 
inflammatory disorders, including kidney 
diseases.
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figure 1 | Schematic illustration of the cholesterol biosynthetic pathway. Sites of action of 
HMG-CoA reductase inhibitors (statins) are indicated, PP pyrophosphate.
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Macroautophagy: a mechanism 
for mediating cell death or for 
promoting cell survival?
Wilfred Lieberthal1
Macroautophagy is a ubiquitous mechanism for the bulk removal 
of macromolecules and cell organelles from the cell. Periyasamy-
Thandavan and colleagues report that cisplatin activates autophagy 
in renal tubular cells and that autophagy plays a role in decreasing 
apoptosis of tubular cells induced by cisplatin. This finding provides 
novel evidence that autophagy may play a role in ameliorating the 
effects of acute injury on the kidney.
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There are three types of autophagy. Micro-
autophagy is a process that has been well 
characterized only in yeast; during this 
process cytosolic components are seques-
tered by lysosomes at the lysosomal mem-
brane by septation and/or invagination. 
Chaperone-mediated autophagy is the 
direct translocation across the lyso-
somal membrane of cytosolic proteins 
that have been ‘tagged’ with a specific 
peptide sequence. This Commentary 
will focus entirely on macroautophagy 
(hereafter referred to as autophagy), 
which is a ubiquitous, genetically pro-
grammed and evolutionarily conserved 
process in which long-lived cytoplasmic 
components, including macromolecular 
aggregates and cellular organelles (such 
as mitochondria, peroxisomes, and endo-
plasmic reticulum), are sequestered into 
vesicles for bulk degradation by a lyso-
somal degradative pathway.1–3
The process of autophagy begins with 
the formation of crescent-shaped ‘ini-
tiation’ membranes that envelop and 
sequester cytosolic components before 
forming double-membraned vesicles called 
autophagosomes (Figure 1). The origin of 
initiation membranes remains uncertain. 
Autophagosomes fuse with lysosomes 
to form autolysosomes, which degrade 
the sequestered contents into their basic 
components (amino acids, fatty acids, 
and so on). These molecules are returned 
to the cytosol for recycling (Figure 1).1–3 
Although the proteasome provides another 
mechanism for mass degradation of pro-
teins, this process requires proteins to be 
tagged by ubiquitination and to be unfolded 
so they can enter the degradative ubiquiti-
nation channel. In contrast, autophagy has 
the ability to degrade all forms of peptide 
and lipid macromolecules as well as entire 
cellular organelles.
Autophagy is a genetically programmed 
process. Autophagy-related genes (ATGs) 
were first isolated in yeast. Subsequently, 
a number of mammalian orthologues of 
yeast ATGs have been identified. These 
genes encode the proteins necessary for 
the complex series of events that consti-
tute the autophagic cycle (Figure 1).1–3 The 
signaling mechanisms responsible for the 
regulation of autophagy remain uncertain. 
However, it is clear that autophagy is acti-
vated by the target of rapamycin complex 1 
(TORC1), as factors that activate TORC1 
(insulin and growth factors) stimulate 
autophagy, and rapamycin-induced inhi-
bition of TORC1 reduces autophagy.2,4,5
The biologic processes controlled by 
autophagy in mammals have not yet been 
clearly elucidated. Paradoxically, current 
evidence appears to suggest that autophagy 
can cause cell death in some situations 
while acting as a prosurvival mechanism 
in others.5 ‘Autophagic cell death’ is pre-
sumed to result from an excessive level of 
cellular autophagy and is a form of pro-
grammed cell death (PCD type II) that is 
morphologically distinct from apoptosis 
(PCD type I).3 Apoptosis is characterized 
by cell shrinkage, DNA fragmentation, and 
the rapid phagocytic removal and degra-
dation of apoptotic cell fragments. In con-
trast, autophagic cell death is associated 
morphologically with the accumulation 
of autophagic vesicles (autophagosomes). 
A fundamental feature that distinguishes 
apoptosis from autophagic cell death is the 
source of the lysosomal enzymes used for 
degrading the dying cells. Apoptotic cells 
are degraded by the lysosomes of phago-
cytic cells, whereas in autophagy the 
endogenous lysosomal machinery of the 
dying cell serves this purpose.5
What data support the view that 
autophagy can cause cell death? There are 
morphologic studies that have demonstrated 
the accumulation of increased numbers of 
dying cells containing many autophago-
somes in some disease states, such as 
degenerative diseases of brain and muscle.3,4 
However, these findings are only correlative 
in nature and cannot be considered direct 
